StocksMedium•21 October 2026•
1 min read
Vivos Therapeutics Regains Nasdaq Listing Compliance
Key Facts
1Vivos Therapeutics announced it received a letter from Nasdaq confirming compliance with the minimum stockholders' equity requirement.
2The company currently meets Listing Rule 5550(b)(1), which requires maintaining stockholders' equity of at least $2.5 million.
Vivos Therapeutics announced it received a letter from Nasdaq confirming compliance with the minimum stockholders' equity requirement. According to a company statement via GlobeNewswire, the firm currently meets Listing Rule 5550(b)(1), which mandates maintaining stockholders' equity of at least $2.5 million.
VVOS closed at $0.1406 on October 20, 2026, the same day the company received the formal notification from Nasdaq staff. The stock traded between a high of $0.1446 and a low of $0.124 during that session, as regaining compliance addresses immediate regulatory concerns regarding its listing status.